TORONTO, April 30, 2015 /CNW/ - Bedrocan Cannabis Corp. (TSXV: BED) ("Bedrocan" or the "Company") will present an update on the Company's progress at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 5, 2015 at 11:00 am Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains represent the world's only standardized (pharmaceutical grade), full-bud medicinal cannabis, and have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research, and has a commitment to quality with ISO 9001-rated production processes and product development, on an international scale. Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol "BED". www.bedrocan.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Bedrocan Cannabis Corp.
For further information: Cam Battley, Bedrocan Cannabis Corp., email@example.com, +1.905.864.5525, www.bedrocan.ca; Investor relations: Jennifer Wood, TMX Equicom, firstname.lastname@example.org, +1.416.815.0700, ext. 226